REGN Jul 2024 970.000 put
| Previous Close | 4.8300 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 4.4000 |
| Strike | 970.00 |
| Expire Date | 2024-07-05 |
| Day's Range | 4.8300 - 4.8300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 26 |
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
